PMC:7600245 / 1271-1595 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":137,"end":145},"obj":"Body_part"},{"id":"T2","span":{"begin":252,"end":255},"obj":"Body_part"},{"id":"T3","span":{"begin":266,"end":269},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"wed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papa"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":204,"end":219},"obj":"Disease"},{"id":"T8","span":{"begin":210,"end":219},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"wed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papa"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":31,"end":40},"obj":"Chemical"},{"id":"T5","span":{"begin":42,"end":54},"obj":"Chemical"},{"id":"T6","span":{"begin":137,"end":145},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_15841"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"wed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papa"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T4","span":{"begin":204,"end":219},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"wed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papa"}

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":83,"end":220},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"wed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papa"}

{"project":"LitCovid-PubTator","denotations":[{"id":"15","span":{"begin":282,"end":286},"obj":"Gene"},{"id":"26","span":{"begin":204,"end":219},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Gene:43740578"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"wed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papa"}